Allarity Therapeutics, Inc. (ALLR) Stock Price & Analysis

Allarity Therapeutics, Inc. (ALLR) fell 2.46% to USD 1.19 as of July 25, 2026 at 20:54 UTC, according to Nexqual real-time market data.

ALLR last closed at USD 1.22; the session ranged USD 1.18–1.25 on volume of 39,464 shares. Market capitalization is $18.93M, with a 52-week range of USD 0.77–2.35 (NCM). Source: Nexqual, July 25, 2026 at 20:54 UTC.

Key Statistics (as of July 25, 2026 at 20:54 UTC)

Technical Analysis (ALLR)

Nexqual's technical model rates ALLR "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 20:54 UTC.

Analyst Ratings (ALLR)

Wall Street analysts rate ALLR "None" based on 1 analysts, with a mean price target of USD 10.25 (range USD 10.25–10.25), per Nexqual as of July 25, 2026 at 20:54 UTC.

Earnings (ALLR)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 20:54 UTC.

Financials & Fundamentals (ALLR)

Source: Nexqual, July 25, 2026 at 20:54 UTC.

Financial Health Score (ALLR)

Nexqual rates Allarity Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 20:54 UTC.

Ownership (ALLR)

Source: Nexqual, July 25, 2026 at 20:54 UTC.

Leadership (ALLR)

Allarity Therapeutics, Inc. is led by Thomas H. Jensen (age 47), Founder, CEO & Director, per Nexqual as of July 25, 2026 at 20:54 UTC.

Major Backers & Investors (ALLR)

Notable institutional backers of Allarity Therapeutics, Inc. include Renaissance Technologies, Fidelity, Two Sigma Investments, LP, according to Nexqual as of July 25, 2026 at 20:54 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 20:54 UTC.

From Allarity Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

• This randomized, biomarker-driven trial is fully funded by the US Veteran's Administration and was opened for enrollment in January 2026.       1 Table of Contents   Allarity ' s DRP ® Companion Diagnostic Platform   Our patented DRP® platform is a proprietary technology that enables the development of cancer drug-specific companion diagnostics that may be used to identify patients most likely to benefit from a particular cancer therapy.
• Sales of FDA-approved PARP inhibitors were approximately $9.0 billion in 2023 and are forecasted to be over $21.0 billion by 2031.   Despite the commercial success of PARP inhibitors, broader adoption is limited by their high rates of GI and bone marrow/ myelo-toxicity.
• Unblinding the clinical benefit data and then comparing to the "prediction" made using the DRP allows us to assess the utility of DRP for potential patient selection.
• Even after we no longer qualify as an emerging growth company, we may still qualify as a "smaller reporting company," which would allow us to continue to take advantage of many of the same exemptions from disclosure requirements, including presenting only the two most recent fiscal years of audited financial statements and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.

Partnerships

• On March 28, 2022, and concurrent with the entry into the Amended License Agreement with LiPlasome Pharma ApS and Chosa, we entered into the LiPlaCis support agreement with Allarity Europe, Smerud, Chosa and LiPlasome (the "Support Agreement").
• These patents would extend the exclusivity period for stenoparib in combination with DRP®-guided patient selection beyond 2040.   Partnerships and Out-Licensing Leverage the DRP ® Platform for Other Cancer Therapeutics   We have also developed external partnerships and out-licensing arrangements to enable the advance of LiPlaCis® leveraging a platinum-specific DRP® companion diagnostic for development in partnership with Chosa Oncology.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 20:54 UTC. This page is informational and not investment advice.